COMPANY
Celldex Therapeutics
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Senior Director, Regulatory Science and CMC Development Strategy | US-MA-Needham | Not stated | Oct 20, 2026 |
| Associate Director, External Drug Product Manufacturing | US-NJ-Hampton | Not stated | Oct 16, 2026 |
| Director, Clinical Supplies | US-NJ-Hampton | Not stated | Oct 16, 2026 |
| Associate Director, Quality Medical Device Engineer | US-NJ-Hampton | Not stated | Oct 16, 2026 |
| Vice President, Commercial Finance | US-NJ-Hampton | Not stated | Oct 16, 2026 |
Timeline
- Trial start Phase 1: A Study of CDX-622 in Participants With Mild to Moderate Asthma source ↗
- Raise Follow-on offering: $345M (total, as published), announced Apr 6, 2026. Source: company release on GlobeNewswire. source ↗
- Trial start Phase 3: A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-anti source ↗
- Trial start Phase 3: Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria source ↗
- Trial start Phase 2: A Study of Barzolvolimab in Patients With Atopic Dermatitis source ↗
- Trial start I: A Phase I Study of CDX-622 source ↗
- Trial start 3: A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) source ↗
- Trial start 3: A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria source ↗
- Trial start Phase 2: A Study of Barzolvolimab in Patients With Prurigo Nodularis source ↗
- Trial start Phase 2: A Study of CDX-0159 in Patients With Eosinophilic Esophagitis source ↗
- Trial start Phase 1: A Study of CDX-585 in Patients With Advanced Malignancies source ↗
- Trial start Phase 2: A Study of CDX-0159 in Patients With Chronic Inducible Urticaria source ↗
- Trial start 2: A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria source ↗
- Trial start Phase 1: A Study of CDX-0159 in Patients With Prurigo Nodularis source ↗
- Trial start 1: A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects source ↗
- Trial start Phase 1: A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria source ↗
- Trial start Phase 1: A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria source ↗
- Trial start Phase 1: A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies source ↗
- Trial start 1: A Phase 1 Study of CDX-0159 source ↗
- Trial start Phase 2: A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma source ↗
- Trial start Phase 1: A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies source ↗
- Trial start Phase 1: A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma source ↗
- Trial start Phase 1: A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors source ↗
- Trial start Phase 1: A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients source ↗
- Trial start Phase 1: A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer source ↗
Upcoming milestones
- 2026-10 (ESTIMATED) · 3 · A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria · NCT06445023
- 2026-10 (ESTIMATED) · 3 · A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) · NCT06455202
- 2027-03 (ESTIMATED) · Phase 1 · A Study of CDX-622 in Participants With Mild to Moderate Asthma · NCT07330778
- 2028-06 (ESTIMATED) · Phase 3 · A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamine · NCT07266402
- 2028-09 (ESTIMATED) · Phase 3 · Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria · NCT07256392
Funding
- Follow-on offering: $345M (total, as published), announced Apr 6, 2026. Source: company release on GlobeNewswire. source ↗
Clinical trials (lead sponsor) 45
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07256392 | Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | Phase 3 | Enrolling by invitation | Nov 25, 2025 | 2028-09 (estimated) |
| NCT07266402 | A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD) | Phase 3 | Recruiting | Jan 15, 2026 | 2028-06 (estimated) |
| NCT06727552 | A Study of Barzolvolimab in Patients With Atopic Dermatitis | Phase 2 | Active, not recruiting | Dec 18, 2024 | May 6, 2026 (actual) |
| NCT06366750 | A Study of Barzolvolimab in Patients With Prurigo Nodularis | Phase 2 | Active, not recruiting | Apr 12, 2024 | Mar 17, 2026 (actual) |
| NCT07330778 | A Study of CDX-622 in Participants With Mild to Moderate Asthma | Phase 1 | Recruiting | Jun 1, 2026 | 2027-03 (estimated) |
| NCT05774184 | A Study of CDX-0159 in Patients With Eosinophilic Esophagitis | Phase 2 | Completed | Jun 1, 2023 | Jun 4, 2025 (actual) |
| NCT06650761 | A Phase I Study of CDX-622 | I | Completed | Nov 1, 2024 | Apr 24, 2026 (actual) |
| NCT06445023 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | 3 | Active, not recruiting | Jul 11, 2024 | 2026-10 (estimated) |
| NCT06455202 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) | 3 | Active, not recruiting | Jul 19, 2024 | 2026-10 (estimated) |
| NCT05405660 | A Study of CDX-0159 in Patients With Chronic Inducible Urticaria | Phase 2 | Completed | Jun 28, 2022 | Jun 12, 2024 (actual) |
| NCT05788484 | A Study of CDX-585 in Patients With Advanced Malignancies | Phase 1 | Completed | May 11, 2023 | May 21, 2025 (actual) |
| NCT05368285 | A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria | 2 | Completed | May 19, 2022 | Sep 28, 2023 (actual) |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | Phase 1 | Completed | Dec 1, 2017 | Sep 13, 2022 (actual) |
| NCT04944862 | A Study of CDX-0159 in Patients With Prurigo Nodularis | Phase 1 | Completed | Nov 8, 2021 | Jul 31, 2023 (actual) |
| NCT04538794 | A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria | Phase 1 | Completed | Sep 24, 2020 | Jan 17, 2023 (actual) |
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | Phase 1 | Completed | Aug 4, 2020 | Apr 6, 2023 (actual) |
| NCT04548869 | A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria | Phase 1 | Completed | Nov 24, 2020 | Dec 16, 2022 (actual) |
| NCT03254927 | A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Terminated | Mar 27, 2018 | Sep 16, 2020 (actual) |
| NCT05031624 | A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects | 1 | Completed | Aug 30, 2021 | Jan 14, 2022 (actual) |
| NCT04146129 | A Phase 1 Study of CDX-0159 | 1 | Completed | Oct 29, 2019 | Apr 6, 2020 (actual) |
| NCT02837991 | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma | Phase 1 | Terminated | 2016-06 | Nov 16, 2018 (actual) |
| NCT01498328 | A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma | Phase 2 | Completed | 2011-12 | 2015-04 (actual) |
| NCT01094496 | A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study) | Phase 2 | Terminated | 2010-04 | 2011-07 (actual) |
| NCT02335918 | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | Phase 1/Phase 2 | Completed | 2015-01 | Dec 12, 2018 (actual) |
| NCT02302339 | A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma | Phase 2 | Terminated | 2014-11 | Jun 14, 2018 (actual) |
| NCT02473731 | A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients | Phase 1 | Completed | 2015-10 | Sep 22, 2016 (actual) |
| NCT02642016 | A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors | Phase 1 | Completed | 2015-12 | Jan 30, 2018 (actual) |
| NCT01997333 | Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer | Phase 2 | Completed | 2013-11 | Nov 30, 2017 (actual) |
| NCT02386111 | A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 | Terminated | 2015-05 | 2017-08 (actual) |
| NCT03067935 | Individual Patient Expanded Access-Glembatumumab Vedotin | Not listed | No longer available | Not listed | Not listed |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Phase 1 | Terminated | 2015-10 | 2017-04 (actual) |
| NCT01460134 | A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers | Phase 1 | Completed | 2011-10 | 2015-12 (actual) |
| NCT01480479 | Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma | III | Completed | 2011-11 | 2016-11 (actual) |
| NCT00458601 | Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme | II | Completed | 2007-08 | 2010-11 (actual) |
| NCT03068650 | Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut | Not listed | No longer available | Not listed | Not listed |
| NCT02456701 | Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379 | Phase 1 | Completed | 2015-06 | Oct 13, 2016 (actual) |
| NCT02014909 | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors | 1 | Completed | 2014-01 | May 25, 2017 (actual) |
| NCT01156753 | A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer | Phase 2 | Completed | 2010-07 | 2012-10 (actual) |
| NCT01465139 | A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers | Phase 1 | Completed | 2011-10 | 2012-11 (actual) |
| NCT02200380 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | Phase 2 | Terminated | 2014-07 | 2016-03 (actual) |
| NCT02413827 | A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma | Phase 1/Phase 2 | Terminated | 2015-04 | Nov 2, 2016 (actual) |
| NCT00948961 | A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 | Phase 1/Phase 2 | Completed | 2009-09 | 2012-06 (actual) |
| NCT01791686 | Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease | Phase 1 | Terminated | 2013-01 | 2014-03 (actual) |
| NCT00709462 | A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01) | Phase 1 | Completed | 2004-03 | 2010-05 (actual) |
| NCT00648102 | Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer | I | Completed | 2006-01 | 2009-05 (actual) |
NIH awards 22
- NIH award 5R44CA192435-05 FY2021: $1,631,702 awarded for that fiscal year; activity R44 (SBIR); PI KELER, TIBOR; recipient as written: CELLDEX THERAPEUTICS, INC., Hampton, NJ. Immune modulation of radiation therapy w source ↗
- NIH award 2R44CA192435-04A1 FY2020: $1,204,513 awarded for that fiscal year; activity R44 (SBIR); PI KELER, TIBOR; recipient as written: CELLDEX THERAPEUTICS, INC., Hampton, NJ. Immune modulation of radiation therapy source ↗
- NIH award 5R44CA192435-03 FY2016: $538,873 awarded for that fiscal year; activity R44 (SBIR); PI KELER, TIBOR; recipient as written: CELLDEX THERAPEUTICS, INC., Hampton, NJ. Immune modulation of radiation therapy wit source ↗
- NIH award 2R44CA192435-02 FY2015: $1,081,749 awarded for that fiscal year; activity R44 (SBIR); PI KELER, TIBOR; recipient as written: CELLDEX THERAPEUTICS, INC., Hampton, NJ. Immune modulation of radiation therapy w source ↗
- NIH award 5R44AI095159-03 FY2015: $988,487 awarded for that fiscal year; activity R44 (SBIR); PI KELER, TIBOR; recipient as written: CELLDEX THERAPEUTICS, INC., Hampton, NJ. Dendritic Cell-Targeted HIV Vaccine Produc source ↗
- NIH award 2R44AI095159-02A1 FY2014: $999,540 awarded for that fiscal year; activity R44 (SBIR); PI KELER, TIBOR; recipient as written: CELLDEX THERAPEUTICS, INC., Hampton, NJ. Dendritic Cell-Targeted HIV Vaccine Prod source ↗
- NIH award 3R41OD018403-01S1 FY2013: $10,528 awarded for that fiscal year; activity R41 (STTR); PI MARSH, HENRY; recipient as written: CELLDEX THERAPEUTICS, INC., Hampton, NJ. CDX-301 and Plerixafor Combination in Ste source ↗
- NIH award 1R41OD018403-01 FY2013: $100,000 awarded for that fiscal year; activity R41 (STTR); PI MARSH, HENRY; recipient as written: CELLDEX THERAPEUTICS, INC., Hampton, NJ. CDX-301 and Plerixafor Combination in Stem source ↗
- NIH contract (government contract; not a grant and not an investment round) 261201200074C-0-0-1 FY2012: $199,398 awarded for that fiscal year; activity N43 (OTHER_NIH); PI n/a; recipient as written: CELLDEX THERAPEUTICS, INC., Hampton, NJ. Immune modulation of source ↗
- NIH award 1R43AI095159-01 FY2011: $297,572 awarded for that fiscal year; activity R43 (SBIR); PI KELER, TIBOR; recipient as written: CELLDEX THERAPEUTICS, INC., Hampton, NJ. Dendritic Cell-Targeted HIV Vaccine Produc source ↗
- NIH award 2R44AI053910-02 FY2006: $750,000 awarded for that fiscal year; activity R44 (SBIR); PI KOCHI, SIMS K; recipient as written: CELLDEX THERAPEUTICS, INC., NEEDHAM, MA. Development and cGMP Manufacture of a Vit source ↗
- NIH award 1R43AI065039-01 FY2005: $130,810 awarded for that fiscal year; activity R43 (SBIR); PI ROLAND, KENNETH L.; recipient as written: CELLDEX THERAPEUTICS, INC., NEEDHAM, MA. Live Attenuated Salmonella Vaccine A source ↗
- NIH award 1R43AI053910-01 FY2003: $126,861 awarded for that fiscal year; activity R43 (SBIR); PI THOMAS, LAWRENCE J; recipient as written: CELLDEX THERAPEUTICS, INC., NEEDHAM, MA. Feasibility Evaluation of an Oral Ty source ↗
- NIH award 1R43AI053021-01 FY2002: $120,511 awarded for that fiscal year; activity R43 (SBIR); PI KOCHI, SIMS K; recipient as written: CELLDEX THERAPEUTICS, INC., NEEDHAM, MA. Live Attenuated Bacterial Vaccines Agains source ↗
- NIH award 1R43NS039234-01A1 FY2000: $103,263 awarded for that fiscal year; activity R43 (SBIR); PI PETTEY, CAROLYN L; recipient as written: CELLDEX THERAPEUTICS, INC., NEEDHAM, MA. SCR1SLEX A DUAL FUNCTION GLYCOPROTE source ↗
- NIH award 1R43AI047510-01 FY2000: $218,442 awarded for that fiscal year; activity R43 (SBIR); PI BEATTIE, DAVID T; recipient as written: CELLDEX THERAPEUTICS, INC., NEEDHAM, MA. DEVELOPMENT OF A REPLICATION-DEFECTIVE source ↗
- NIH award 5R44HL057149-03 FY1998: $304,770 awarded for that fiscal year; activity R44 (SBIR); PI RITTERSHAUS, CHARLES; recipient as written: CELLDEX THERAPEUTICS, INC., NEEDHAM, MA. DEVELOPMENT OF A TRANSGENIC RAT AT source ↗
- NIH award 1R43HL059122-01A1 FY1998: $96,407 awarded for that fiscal year; activity R43 (SBIR); PI THOMAS, LAWRENCE J; recipient as written: CELLDEX THERAPEUTICS, INC., NEEDHAM, MA. PEPTIDE VACCINE TO PREVENT/TREAT AT source ↗
- NIH award 2R44HL057149-02 FY1997: $373,216 awarded for that fiscal year; activity R44 (SBIR); PI RITTERSHAUS, CHARLES; recipient as written: CELLDEX THERAPEUTICS, INC., NEEDHAM, MA. DEVELOPMENT OF A TRANSGENIC RAT AT source ↗
- NIH award 1R43HL057045-01A1 FY1997: $99,999 awarded for that fiscal year; activity R43 (SBIR); PI THOMAS, LAWRENCE J; recipient as written: CELLDEX THERAPEUTICS, INC., NEEDHAM, MA. PLASMID BASED VACCINE TO PREVENT/TR source ↗
- NIH award 1R43HL057149-01 FY1996: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI MAKRIDES, SAVVAS C; recipient as written: CELLDEX THERAPEUTICS, INC., NEEDHAM, MA. DEVELOPMENT OF A TRANSGENIC RAT ATHE source ↗
- NIH award 1R43CA042699-01 FY1986: $49,994 awarded for that fiscal year; activity R43 (SBIR); PI PICKERING, LULU; recipient as written: CELLDEX THERAPEUTICS, INC., NEEDHAM, MA. T CELL RECOGNITION OF LUNG CANCERS IN MA source ↗
Open jobs 46
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Senior Director, Regulatory Science and CMC Development Strategy | US-MA-Needham | Not stated | Oct 20, 2026 | Not stated |
| Associate Director, External Drug Product Manufacturing | US-NJ-Hampton | Not stated | Oct 16, 2026 | Senior |
| Director, Clinical Supplies | US-NJ-Hampton | Not stated | Oct 16, 2026 | Senior |
| Associate Director, Quality Medical Device Engineer | US-NJ-Hampton | Not stated | Oct 16, 2026 | Senior |
| Vice President, Commercial Finance | US-NJ-Hampton | Not stated | Oct 16, 2026 | Executive |
| Manager, Biologics Drug Substance External Manufacturing | US-NJ-Hampton | Not stated | Oct 16, 2026 | Mid |
| Senior Manager, Biologics Manufacturing Technical Support | US-NJ-Hampton | Not stated | Oct 16, 2026 | Senior |
| Vice President, Corporate Controller | US-NJ-Hampton | Not stated | Oct 16, 2026 | Executive |
| Senior Director, HCP Marketing - Hampton, NJ | US-NJ-Hampton | Not stated | Oct 16, 2026 | Senior |
| Computer Validation Engineer IV | US-MA-Fall River | Not stated | Oct 16, 2026 | Senior |
| Associate Director, Full-Stack Engineer, Commercial | US-NJ-Hampton | Not stated | Oct 16, 2026 | Senior |
| Executive Director, Stakeholder Advocacy (Remote) | US-NJ-Hampton | Not stated | Oct 16, 2026 | Executive |
| Quality Assurance Associate II | US-MA-Fall River | Not stated | Oct 16, 2026 | Mid |
| Associate Director, Drug Substance | US-NJ-Hampton | Not stated | Oct 16, 2026 | Senior |
| Senior Director, US HEOR - Hampton, NJ | US-NJ-Hampton | Not stated | Oct 16, 2026 | Senior |
| Research Associate | US-NJ-Hampton | Not stated | Oct 16, 2026 | Entry |
| Senior Director, Clinical Science | US-NJ-Hampton | Not stated | Oct 16, 2026 | Senior |
| Director, Clinical Science | US-NJ-Hampton | Not stated | Oct 16, 2026 | Senior |
| Vice President, US Sales | US-NJ-Hampton | Not stated | Oct 16, 2026 | Executive |
| Executive Director, Managed Markets - National and Key Accounts (Remote) | US-NJ-Hampton | Not stated | Oct 16, 2026 | Executive |
| Senior Manager, Field Medical Science Liaison, Mid Atlantic (NJ/Phil) | US-PA-Philadelphia | Not stated | Oct 16, 2026 | Senior |
| Senior Manager, Field Medical Science Liaison, Great Lakes (Michigan/Ohio) | US-NJ-Hampton | US-MI | Not stated | Oct 16, 2026 | Senior |
| Senior Manager, Field Medical Science Liaison, Mid-South (Tennessee/Kentucky) | US-TN-Nashville | Not stated | Oct 16, 2026 | Senior |
| Senior Manager, Field Medical Science Liaison, North Texas/Oklahoma | US-TX-Dallas | Not stated | Oct 16, 2026 | Senior |
| Senior HR Partner | US-CT-New Haven | Not stated | Oct 16, 2026 | Senior |
| Associate Director, Biostatistics | US-MA-Needham | Not stated | Oct 16, 2026 | Senior |
| Director, Scientific Publications - Hampton, NJ | US-NJ-Hampton | Not stated | Oct 16, 2026 | Senior |
| Sr. Director, Medical Evidence Generation, Immunology - Hampton, NJ | US-NJ-Hampton | Not stated | Oct 16, 2026 | Senior |
| Materials Handler I | US-MA-Fall River | Not stated | Oct 16, 2026 | Entry |
| Sr. Director, Epidemiology, Immunology - Hampton, NJ | US-NJ-Hampton | Not stated | Oct 16, 2026 | Senior |
| Executive Medical Science Liaison _ Northwest | US-NJ-Hampton | US-WA-Seattle | Not stated | Oct 16, 2026 | Mid |
| Director, Scientific Communications - Hampton, NJ | US-NJ-Hampton | Not stated | Oct 16, 2026 | Senior |
| Senior Medical Science Liaison _ South Central | US-NJ-Hampton | US-TX-Dallas | US-TX-Houston | Not stated | Oct 16, 2026 | Senior |
| Senior Medical Science Liaison _ Mountain West | US-NJ-Hampton | US-CO-Denver | Not stated | Oct 16, 2026 | Senior |
| Senior Medical Science Liaison _ North Central | US-NJ-Hampton | US-IL-Chicago | Not stated | Oct 16, 2026 | Senior |
| Executive Medical Science Liaison _ Washington DC | US-NJ-Hampton | US-DC-Washington | Not stated | Oct 16, 2026 | Mid |
| Senior Medical Science Liaison _ Southeast | US-NJ-Hampton | US-GA-Atlanta | Not stated | Oct 16, 2026 | Senior |
| Senior Medical Science Liaison _ New York | US-NJ-Hampton | US-NY-New York | Not stated | Oct 16, 2026 | Senior |
| Director, Supply Chain Planner - Commercial | US-NJ-Hampton | Not stated | Oct 16, 2026 | Senior |
| Vice President, Pharmacovigilance & Risk Management | US-NJ-Hampton | Not stated | Oct 16, 2026 | Executive |
| Global Clinical Project Leader | US-CT-New Haven | US-NJ-Hampton | Not stated | Oct 16, 2026 | Senior |
| Regional Director, Medical Science Liaison - West | US-CA-Los Angeles | US-CA-San Francisco | US-WA-Seattle | Not stated | Oct 16, 2026 | Senior |
| Senior Director, Commercial Learning and Development and Onboarding | US-NJ-Hampton | Not stated | Oct 16, 2026 | Senior |
| Regional Director, Medical Science Liaison - East | US-PA-Philadelphia | US-MA-Boston | US-FL-Miami | US-NC-Raleigh | US-DC-Washington | Not stated | Oct 16, 2026 | Senior |
| Executive Director, Medical Affairs | US-NJ-Hampton | Not stated | Oct 16, 2026 | Executive |
| Executive Director, Trade & Distribution | US | US-MA-Boston | US-TN-Nashville | US-NC-Raleigh | US-PA-Philadelphia | Not stated | Oct 16, 2026 | Executive |
Connect
See your connections at Celldex Therapeutics on LinkedIn (search by name, results not checked)